The stock of Nuvation Bio Inc (NUVB) has gone up by 6.44% for the week, with a 7.83% rise in the past month and a -30.14% drop in the past quarter. The volatility ratio for the week is 6.01%, and the volatility levels for the past 30 days are 7.31% for NUVB. The simple moving average for the past 20 days is 6.53% for NUVB’s stock, with a -8.18% simple moving average for the past 200 days.
Is It Worth Investing in Nuvation Bio Inc (NYSE: NUVB) Right Now?
Company’s 36-month beta value is 1.36.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for NUVB is 227.21M, and currently, short sellers hold a 4.39% ratio of that floaft. The average trading volume of NUVB on October 30, 2024 was 1.49M shares.
NUVB) stock’s latest price update
Nuvation Bio Inc (NYSE: NUVB) has experienced a rise in its stock price by 5.08 compared to its previous closing price of 2.36. However, the company has seen a gain of 6.44% in its stock price over the last five trading days. businesswire.com reported 2024-10-07 that NEW YORK–(BUSINESS WIRE)–Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced the appointment of Philippe Sauvage as Chief Financial Officer (CFO). Mr. Sauvage brings over 20 years of global leadership experience in finance, operations, and commercialization within healthcare and biopharmaceutical organizations. Most recently, as Global Head of Operations and Access at Sanofi, he oversaw.
Analysts’ Opinion of NUVB
Many brokerage firms have already submitted their reports for NUVB stocks, with Jefferies repeating the rating for NUVB by listing it as a “Buy.” The predicted price for NUVB in the upcoming period, according to Jefferies is $10 based on the research report published on March 27, 2024 of the current year 2024.
BTIG Research, on the other hand, stated in their research note that they expect to see NUVB reach a price target of $5. The rating they have provided for NUVB stocks is “Buy” according to the report published on March 26th, 2024.
Jefferies gave a rating of “Hold” to NUVB, setting the target price at $2 in the report published on January 06th of the previous year.
NUVB Trading at -6.01% from the 50-Day Moving Average
After a stumble in the market that brought NUVB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.38% of loss for the given period.
Volatility was left at 7.31%, however, over the last 30 days, the volatility rate increased by 6.01%, as shares surge +7.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.25% lower at present.
During the last 5 trading sessions, NUVB rose by +1.93%, which changed the moving average for the period of 200-days by +49.37% in comparison to the 20-day moving average, which settled at $2.32. In addition, Nuvation Bio Inc saw 64.24% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NUVB starting from Mashal Robert, who purchase 100,000 shares at the price of $2.20 back on Oct 08 ’24. After this action, Mashal Robert now owns 100,000 shares of Nuvation Bio Inc, valued at $220,000 using the latest closing price.
Cui Xiangmin, the Director of Nuvation Bio Inc, purchase 277,895 shares at $2.97 during a trade that took place back on Jun 25 ’24, which means that Cui Xiangmin is holding 2,453,131 shares at $825,348 based on the most recent closing price.
Stock Fundamentals for NUVB
Current profitability levels for the company are sitting at:
- -66.32 for the present operating margin
- -0.04 for the gross margin
The net margin for Nuvation Bio Inc stands at -300.6. The total capital return value is set at -0.21. Equity return is now at value -115.83, with -82.63 for asset returns.
Based on Nuvation Bio Inc (NUVB), the company’s capital structure generated 0.53 points at debt to capital in total, while cash flow to debt ratio is standing at -0.29. The debt to equity ratio resting at 1.12. The interest coverage ratio of the stock is -22.87.
Currently, EBITDA for the company is -99.6 million with net debt to EBITDA at -2.27. When we switch over and look at the enterprise to sales, we see a ratio of 635.53. The receivables turnover for the company is 0.42for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.49.
Conclusion
In a nutshell, Nuvation Bio Inc (NUVB) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
